HOME >> BIOLOGY >> NEWS
Gene expression pattern could lead to improved treatment of pediatric septic shock

CINCINNATI A consortium of researchers headed by Cincinnati Childrens Hospital Medical Center has discovered a gene expression pattern that could lead to improved diagnosis and treatment of pediatric septic shock still a serious public health problem despite todays potent antibiotics and pediatric intensive care units.

Consistent with Cincinnati Childrens increased emphasis on personalized and predictive medicine where diagnosis and treatment coincide with a person's genetic predisposition the study involves the largest gene expression analysis to date of blood samples from children with septic shock. It found new evidence linking adverse clinical outcomes with the decreased expression of genes that encode proteins involved in zinc regulation. This unexpected finding suggests these proteins and zinc regulation could provide a target for therapeutic intervention to inhibit septic shocks progression to multiple organ failure.

Zinc was not even on our radar screen for this disease process, said Dr. Hector Wong, M.D., professor of Pediatrics and director of Critical Care Medicine at Cincinnati Childrens. This study demonstrates the potential power of genomic medicine for discovery and the generation of novel hypotheses. We are ultimately interested in determining whether or not there are biologically significant gene expression profiles that distinguish survivors from non-survivors. The rationale is to discover novel biomarkers of poor outcome and novel therapeutic targets as means for developing more effective treatment strategies.

The study published in the July issue of Physiological Genomics and consortium were led by Dr. Wong. The paper describes how comparative gene expression analysis of blood samples from children identified 63 genes expressed differently in patients with septic shock. This includes two forms of metallothionein where higher levels of metallothionein and lower levels of zinc were associated with increased
'"/>

Contact: Nick Miller
513-803-6035
Cincinnati Children's Hospital Medical Center
26-Jul-2007


Page: 1 2

Related biology news :

1. A low expression of MX2 gene exists in the white blood cells of narcoleptics
2. Boston Univeristy bioengineers devise dimmer swith to regulate gene expression in mammal cells
3. Clocking in and out of gene expression
4. High cholesterol diets modify gene expression in atherosclerosis
5. Gene expression patterns predict rapid decline in idiopathic pulmonary fibrosis patients
6. Decoding gene expression in cancer tumors using noninvasive imaging
7. Growing nerve cells in 3-D dramatically affects gene expression
8. XDx to present recent success with AlloMap molecular expression testing
9. Fat tissue-derived hormone leptin increases e-cadherin expression, obesity-breast cancer link noted
10. Clues to gene expression in cystic fibrosis will guide research
11. Protein overexpression at heart of heart failure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... 08, 2020 , ... Overcoming Comparability Issues in Regenerative Medicines ... Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, https://www.fdanews.com/cellandgenetherapy , ... way to complete one? Will the study comply with all FDA requirements? Understanding ...
(Date:7/1/2020)... N.J. (PRWEB) , ... July 01, 2020 , ... ... announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in ... the company’s existing Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... monoclonal antibody development services, today announced that the company has received ISO9001:2015 ... the pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation ...
Breaking Biology News(10 mins):
(Date:7/1/2020)... (PRWEB) , ... June 30, ... ... expert tissue data insights, today announced that the launch of a new ... along with data about the tumor microenvironment (TME). , “Flagship’s TissueInsight is ...
(Date:6/28/2020)... , ... June 25, 2020 , ... ... advance photodynamic therapy for treating cancer, today announced the company has entered a ... Park”). The agreement provides Lumeda globally exclusive rights to Roswell Park intellectual ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the premier provider ... Derek Fournier has been appointed CEO and President. Founder and former CEO, David ... , “DeCurtis Corporation has been on an incredible journey for the last twenty ...
(Date:6/23/2020)... (PRWEB) , ... June 23, 2020 , ... ... innovative CNS therapies, today announced that it has filed an Investigational New Drug ... Phase 2b clinical trial of its lead drug candidate NBTX-001 in patients with ...
Breaking Biology Technology:
Cached News: